Projected Health Expenditures of Precision Medicine Under a Value-Based Pricing Framework
Open Access
- 14 September 2026
- journal article
- research article
- Published by Springer Nature in Operations Research Forum
- Vol. 7 (3) , 107
Abstract
Precision medicine (PM) has the potential to improve healthcare by tailoring treatments to individual genetic, environmental, and lifestyle factors. However, its high initial costs pose challenges for achieving cost neutrality within healthcare budgets. This study investigates the cost implications of PM through a value-based pricing (VBP) framework. A mathematical model was used to evaluate the economic impact of PM, specifically considering three major cost factors: the optimization of existing therapies through the application of new biomarkers, which can reduce ineffective treatments by better identifying patient subgroups; the development of targeted drugs designed to interact with specific biomarkers, offering higher efficacy but often at premium pricing; and the costs associated with early disease detection and diagnosis, where PM’s emphasis on proactive screening aims to identify conditions at earlier, more treatable stages but introduces additional diagnostic expenditures. The model incorporated drug pricing and market dynamics relevant to the German social health insurance context. Although PM may generate savings under favorable assumptions, the analysis indicates that, in the German base case, the transition to PM is projected to increase annual healthcare costs by approximately €2.6 billion over the next 10 to 20 years. Sensitivity analysis shows substantial uncertainty around this estimate: In the best-case scenario, PM is projected to yield annual net savings of €1.6 billion, whereas in the worst-case scenario total annual PM expenditures rise to €34.7 billion. The findings therefore suggest that the budget impact of PM depends strongly on treatment effectiveness, competition among drug and biomarker producers, and pricing dynamics for new targeted therapies. However, under the current German base case assumptions, PM is not cost neutral and is projected to increase expenditures. Its economic sustainability depends critically on effective competition, pricing discipline for new targeted drugs and biomarkers, and policy measures that support efficient implementation.Keywords
Funding Information
- Frankfurt School of Finance & Management gGmbH
This publication has 27 references indexed in Scilit:
- In search of biomarkers for prediction of drug treatment responses in rheumatoid arthritis: Lessons learned and future perspectivesAutoimmunity Reviews, 2025
- MT53 Cost Analysis of In-House NGS Testing for Non-Small Cell Lung Cancer in GermanyValue in Health, 2024
- Fifty years of operational research applied to healthcareEuropean Journal of Operational Research, 2024
- Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and SwitzerlandJAMA Health Forum, 2024
- Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2Pathology - Research and Practice, 2024
- Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice SettingClinical Lung Cancer, 2023
- Arzneiverordnungen 2022 im Überblick2023
- The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression AnalysisValue in Health, 2022
- International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the LiteratureValue in Health Regional Issues, 2020
- Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation ModelingValue in Health, 2020